Citation Tools
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
THU0146 Impact of anti-Drug Antibodies on Efficacy and Safety Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- THU0146 Impact of anti-Drug Antibodies on Efficacy and Safety Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy